New Treatment Target Found for Prostate Cancer Tumors

A new group of molecules has been identified that could be targeted to slow tumor growth in prostate cancer patients.

A 3-year research project involved the use of an advanced screening technique called RNA-sequencing, which found that hundreds of genes were affected by testosterone, according to findings published in EBioMedicine. Of the 700 genes identified, an important set that added glycans to the surface of prostate cancer cells was found. This group of genes has never been investigated before.

The results of the study suggest that testosterone changes glycans to make cancer cells more likely to grow, survive, and spread to other areas of the body. By targeting these glycans, researchers believe it may have the potential to stop tumor growth and metastasis.

“Our findings are very significant for future treatments as they identify a new group of molecules in prostate cancer which could be targeted therapeutically,” said co-lead researcher Jennifer Munkley. “Now (that) we have identified these glycans we will be able to develop strategies to inhibit them and help patients with this condition.”

According to the study, 1 in 8 men will be diagnosed with prostate cancer. Authors noted that glycans have the potential to be used as part of a diagnostic test to help physicians decide which prostate cancers are in need of treatment.

“Treatments targeting glycan sugar groups have been developed for other types of illness, such as breast cancer,” Munkley said. “Our results mean these treatments could also be used for prostate cancer.”
 

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Atezolizumab (Tecentriq) approved by FDA in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of metastatic nonsquamous non-small cell lung cancer.
An analysis indicates that immune-related adverse events may be more common than initially reported in the clinical trials for these therapies.
As biosimilar development continues to grow, pharmacists will be essential in transitioning both clinicians and patients alike in the use of these therapies.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$